Gundolf Schneider

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann, Justin Ferdinandus, Gundolf Schneider et al. · The Lancet · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +15

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Peter Borchmann, Alden A. Moccia, Richard Greil et al. · Blood · 2022 · 14 citations

Medicine, Oncology, Chemotherapy +9

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Peter Borchmann, Alden A. Moccia, Richard Greil et al. · Blood · 2023 · 11 citations

Pharmacy, Oncology, Palliative Care +6

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Justin Ferdinandus, Helen Kaul, Alexander Fosså et al. · Blood · 2024 · 11 citations · Full text

Medicine, Hematology, Oncology +14

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

Justin Ferdinandus, Gundolf Schneider, Alden A. Moccia et al. · The Lancet Oncology · 2025 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +13